Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
Ian G
IG
Cowell
Caroline A
CA
Austin
D018943:Anthracyclines / Q000378:metabolism / Q000633:toxicity; D053903:DNA Breaks, Double-Stranded / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D015251:Epirubicin / Q000378:metabolism / Q000633:toxicity; D005047:Etoposide / Q000378:metabolism / Q000633:toxicity; D006801:Humans; D007938:Leukemia / Q000235:genetics*; D008942:Mitoxantrone / Q000378:metabolism / Q000633:toxicity; D008957:Models, Genetic; D016609:Neoplasms, Second Primary / Q000235:genetics*; D000075223:Poly-ADP-Ribose Binding Proteins; D014178:Translocation, Genetic / Q000187:drug effects* / Q000235:genetics
D018943:Anthracyclines; D004268:DNA-Binding Proteins; D000075223:Poly-ADP-Ribose Binding Proteins; D015251:Epirubicin; D005047:Etoposide; D008942:Mitoxantrone; D004250:DNA Topoisomerases, Type II; C000618814:TOP2B protein, human